论文信息 - Efficacy and safety of fezakinumab (an IL‐22 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double‐blind, phase 2a trial - 字舞流文

Efficacy and safety of fezakinumab (an IL‐22 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double‐blind, phase 2a trial

M. Lebwohl | A. Neumann | G. Singer | J. Krueger | S. Garcet | J. Fuentes-Duculan | P. Gilleaudeau | M. Sullivan-Whalen | Xuan Li | P. Brunner | E. Guttman‐Yassky | C. Traidl‐Hoffmann | A. Pavel | Y. Estrada | S. Khattri | K. Malik | S. Rose | D. Baum | S. J. On | E. Guttman-Yassky | Giselle K. Singer | Danielle Baum